In:
Journal of Heterocyclic Chemistry, Wiley, Vol. 54, No. 1 ( 2017-01), p. 450-456
Abstract:
A series of new 2‐methyl‐2‐[(1,3‐Diethyl‐2,6‐dioxo‐2,3,6,7‐tetrahydro‐1 H ‐purin‐8‐yl)thio]‐ N ‐ substituted arylacetamides were synthesized. The antitumor activity of these purine based compounds were evaluated on breast cancer (MCF7) and leukemic cancer (K562) cell lines via cell viability assay utilizing the tetrazolium dye 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT). These results were substantiated using computer docking experiments (LigandFit docking engine and PMF scoring function) which predict that the antitumor activity of these new compounds may be attributable to their abilities to effectively bind and block oncogenic tyrosine kinases, particularly bcr/abl.
Type of Medium:
Online Resource
ISSN:
0022-152X
,
1943-5193
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2042274-X
